A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: Correlation between clinical responses and AUC pharmacokinetics
- Carla Casulo
- , Julie M. Vose
- , William Y. Ho
- , Brad Kahl
- , Mark Brunvand
- , Andre Goy
- , Yvette Kasamon
- , Bruce Cheson
- , Jonathan W. Friedberg
Research output: Contribution to journal › Article › peer-review
16
Link opens in a new tab
Scopus
citations